Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …

The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Importance Platelets represent a potential therapeutic target for improved clinical outcomes
in patients with COVID-19. Objective To evaluate the benefits and risks of adding a P2Y12 …

Summary COVID-19, caused by SARS-CoV-2, is characterised by a broad spectrum of
symptom severity that requires varying amounts of care according to the different stages of …

Background We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor,
for the treatment of patients admitted to hospital with COVID-19. Methods This randomised …

The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …

Methods| The details of the trial have been previously reported (Supplement 1 and
Supplement 2). 3 Institutional review board approval was provided by Comités de Protection …

Abstract Coronavirus disease 2019 (COVID-19) is especially severe in aged populations.
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …